Extensively drug-resistant tuberculosis
disease diseaseOn this page
Also known as XDR-TB
Summary
Extensively drug-resistant tuberculosis (MONDO:0100482) is a disease and 13 clinical trials. Top therapeutic interventions include linezolid, bedaquiline, and clofazimine. A subtype of drug-resistant tuberculosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 13
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | extensively drug-resistant tuberculosis |
| Mondo ID | MONDO:0100482 |
| MeSH | D054908 |
| NCIT | C128417 |
| UMLS | C1827301 |
| MedGen | 321809 |
| GARD | 0026240 |
| Is cancer (heuristic) | no |
Also known as: XDR-TB
Disease family
This is a subtype of drug-resistant tuberculosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › tuberculosis › drug-resistant tuberculosis › extensively drug-resistant tuberculosis
Related subtypes (3): multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis, totally drug-resistant tuberculosis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 13.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2/PHASE3 | 4 |
| Not specified | 3 |
| PHASE3 | 2 |
| PHASE2 | 2 |
| PHASE4 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01521364 | PHASE4 | COMPLETED | Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients |
| NCT02454205 | PHASE2/PHASE3 | COMPLETED | An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis |
| NCT02589782 | PHASE2/PHASE3 | COMPLETED | Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) |
| NCT03086486 | PHASE3 | COMPLETED | Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis |
| NCT04062201 | PHASE3 | COMPLETED | Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care |
| NCT04081077 | PHASE2/PHASE3 | UNKNOWN | PRACTECAL-PKPD Sub Study |
| NCT04207112 | PHASE2/PHASE3 | COMPLETED | Economic Evaluation of New MDR TB Regimens |
| NCT00664313 | PHASE1/PHASE2 | COMPLETED | TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB |
| NCT00685360 | PHASE2 | COMPLETED | A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB) |
| NCT00727844 | PHASE2 | COMPLETED | Linezolid to Treat Extensively-Drug Resistant Tuberculosis |
| NCT01212003 | Not specified | RECRUITING | Training Protocol on the Natural History of Tuberculosis |
| NCT01071603 | Not specified | COMPLETED | Tuberculosis in China |
| NCT05175794 | Not specified | COMPLETED | Triage Test for All Oral DR-TB Regimen (TRiAD Study) |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| LINEZOLID | 4 | 7 |
| BEDAQUILINE | 4 | 6 |
| CLOFAZIMINE | 4 | 4 |
| MOXIFLOXACIN | 4 | 4 |
| PRETOMANID | 4 | 4 |
| ISONIAZID | 4 | 2 |
| PYRAZINAMIDE | 4 | 2 |
| DELAMANID | 4 | 1 |
| ETHAMBUTOL | 4 | 1 |
| ETHIONAMIDE | 4 | 1 |
| KANAMYCIN | 4 | 1 |
| BEKANAMYCIN | 3 | 1 |
| TERIZIDONE | 2 | 1 |
| CHEMBL4746300 | 0 | 4 |
| CHEMBL5285059 | 0 | 1 |